**Appendix Table E103. Results from studies assessing the ability of PFA-100 to predict other clinical events in patients with ischemic heart disease**

| **Author, year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Malek, 2007  17295159  Poland  NR | Clopidogrel LD 300 or 600mg and maintaining 75mg daily | PFA-100 | Recurrent angina | Recurrent angina | In-hospital 6 days | Groups 1-3 | Recurrent angina | 2/29 (6.9) | OR=4.5 (calculated) | 0.4-52 | p=0.23  groups 1-3 vs control  Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Control |  | 1/62 (1.6) |  |  |  |  |  |  |
|  | Clopidogrel LD 300 or 600mg and maintaining 75mg daily | PFA-100 | Arrhythmia | Arrhythmia | In-hospital 6 days | Groups 1-3 | Arrhythmia | 3/29 (10.3) | OR=3.5 (calculated) | 0.5-22 | p=0.19  groups 1-3 vs control  Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Control |  | 2/62 (3.2) |  |  |  |  |  |  |
|  | Clopidogrel LD 300 or 600mg and maintaining 75mg daily | PFA-100 | Pulmonary oedema | Pulmonary oedema | In-hospital 6 days | Groups 1-3 | Pulmonary oedema | 1/29 (3.4) | OR=2.2 (calculated0 | 0.1-36.1 | p=0.59  groups 1-3 vs control  Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Control |  | 1/62 (1.6) |  |  |  |  |  |  |
|  | Clopidogrel LD 300 or 600mg and maintaining 75mg daily | PFA-100 | Cardiogenic shock | Cardiogenic shock | In-hospital 6 days | Groups 1-3 | Cardiogenic shock | 3/29 (10.3) | OR=16.5(calculated) | 0.8-330.9 | p=0.07  groups 1-3 vs control  Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Control |  | 0/62 (0) |  |  |  |  |  |  |
| Huczek,  2008  18301358  Poland  NR | Clopidogrel 75 mg | Combination of CT-EPI and CT-ADP by PFA-100 | rehospitalization for CHF | rehospitalization for CHF | 6 months | Group I (complete platelet function inhibition) | rehospitalization for CHF | 2 | NR | NR | P<0.001  P for trend  [ANOVA] | NO | NR |  |
|  |  |  |  |  |  | Group II (partial platelet function inhibition) |  | 3 |  |  |  |  |  |  |
|  |  |  |  |  |  | Group III (no platelet function inhibition). |  | 12 |  |  |  |  |  |  |